EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure

Sook Jin Seong iD, O Seong Kweon iD, Young-Ran Yoon iD, Yu Kyung Kim iD, Yoo Na Kang iD, Se Young Jang iD

British Journal of Clinical Pharmacology · 2025-11 · 91 (11) · 3266-3271

DOI: 10.1002/bcp.70245 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 20.08.2025. Verfasst von Sook Jin Seong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Ko…. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fexuprazan, a potassium‐competitive acid blocker, is increasingly used for the treatment of gastroesophageal reflux disease in South Korea. While generally well tolerated, data regarding its hepatotoxic potential are scarce. We report a case of idiosyncratic drug‐induced liver injury in a 61‐year‐old woman following 2 months of fexuprazan therapy. She presented with fatigue and elevated liver enzymes, and liver biopsy demonstrated single‐cell necrosis, interface hepatitis and eosinophilic infiltration—features consistent with drug‐induced liver injury. Her liver function normalized after drug discontinuation. However, approximately 20 months later, the patient experienced a recurrence of liver injury after unintentionally being prescribed fexuprazan again. The second episode showed similar biochemical and histological features, fulfilling Hy's law criteria and increasing the RUCAM score from probable to highly probable . Pharmacokinetic analysis during the first episode revealed a prolonged elimination half‐life, suggestive of impaired metabolism during active hepatic injury. Pharmacogenetic testing revealed a cytochrome P450 enzyme 2C19 poor metabolizer genotype, although its clinical relevance was limited in this case. This report highlights a rare but reproducible adverse drug reaction to fexuprazan and emphasizes the importance of thorough drug history and postmarketing surveillance. To our knowledge, this is the first report of recurrent fexuprazan‐induced liver injury confirmed by unintentional re‐exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemical and Drug Induced Liver InjuryHumansFemaleMiddle AgedRecurrenceCytochrome P-450 CYP2C19LiverGastroesophageal Reflux

Stichwörter der Autor:innen

drug rechallengedrug‐induced liver injuryfexuprazanpharmacogenomicspharmacokineticspotassium‐competitive acid blocker

Substanzen

Cytochrome P-450 CYP2C19CYP2C19 protein, human

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea.
  • Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea.
  • Department of Laboratory Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea.
  • Department of Forensic Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.

ORCID-Profile: Sook Jin Seong, O Seong Kweon, Young-Ran Yoon, Yu Kyung Kim, Yoo Na Kang, Se Young Jang

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Seong, S. J., Kweon, O. S., Yoon, Y. R., Kim, Y. K., Kang, Y. N., & Jang, S. Y. (2025). Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure. British Journal of Clinical Pharmacology, 91(11), 3266-3271. https://doi.org/10.1002/bcp.70245

Vancouver

Seong SJ, Kweon OS, Yoon YR, Kim YK, Kang YN, Jang SY. Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure. British Journal of Clinical Pharmacology. 2025;91(11):3266-3271. doi:10.1002/bcp.70245

BibTeX
@article{Seong2025,
  author = {Seong, Sook Jin and Kweon, O Seong and Yoon, Young-Ran and Kim, Yu Kyung and Kang, Yoo Na and Jang, Se Young},
  title = {Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {11},
  pages = {3266--3271},
  doi = {10.1002/bcp.70245}
}
Kostenlos starten →